{"entity":{"type":"insider","cik":"0001341637","url":"/insider/0001341637","json_url":"/insider/0001341637.json","name":"Kiley Alison","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":5,"first":"2007-11-13","last":"2012-10-17","span_basis":"filed_date"},"name_variants":[{"name":"Kiley Alison","source":"filing","n_filings":4,"first_seen":"2010-10-27","last_seen":"2012-10-17"},{"name":"Peyromaure de Bord Alison","source":"filing","n_filings":1,"first_seen":"2007-11-13","last_seen":"2007-11-13"}],"transactions":[{"id":2163996,"accession":"0001209191-12-049852","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-12-049852","line_url":"/filing/0001209191-12-049852","is_derivative":false,"issuer_cik":"0001198321","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001198321","owner_cik":null,"owner_name":"ALTA BIOPHARMA PARTNERS III LP; CHAMPSI FARAH; ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG; HURWITZ EDWARD; ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC; ALTA BIOPHARMA MANAGEMENT III LLC; PENHOET EDWARD; Kiley Alison","owner_display_name":"ALTA BIOPHARMA PARTNERS III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":140000.0,"shares_display":"140,000","price_per_share":18.67,"price_display":"18.67","price_state":"stated","total_value":2613800.0,"total_display":"2,613,800.00","total_whole":"2,613,800","shares_owned_after":2280197.0,"shares_owned_after_display":"2,280,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-10-16","filed_date":"2012-10-17","scope":"insider","n_lines":3},{"id":2163985,"accession":"0001209191-12-049852","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-12-049852","line_url":"/filing/0001209191-12-049852","is_derivative":false,"issuer_cik":"0001198321","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001198321","owner_cik":null,"owner_name":"ALTA BIOPHARMA PARTNERS III LP; CHAMPSI FARAH; ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG; HURWITZ EDWARD; ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC; ALTA BIOPHARMA MANAGEMENT III LLC; PENHOET EDWARD; Kiley Alison","owner_display_name":"ALTA BIOPHARMA PARTNERS III LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60733.0,"shares_display":"60,733","price_per_share":17.54,"price_display":"17.54","price_state":"stated","total_value":1065256.82,"total_display":"1,065,256.82","total_whole":"1,065,257","shares_owned_after":2408426.0,"shares_owned_after_display":"2,408,426","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-10-15","filed_date":"2012-10-17","scope":"insider","n_lines":3},{"id":9096502,"accession":"0001209191-11-043226","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-11-043226","line_url":"/filing/0001209191-11-043226#line-2","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001341637","owner_name":"Kiley Alison","owner_display_name":"Kiley Alison","owner_url":"/insider/0001341637","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5500.0,"shares_display":"5,500","price_per_share":12.454,"price_display":"12.45","price_state":"stated","total_value":68497.0,"total_display":"68,497.00","total_whole":"68,497","shares_owned_after":2690251.0,"shares_owned_after_display":"2,690,251","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-08-09","filed_date":"2011-08-09","scope":"insider"},{"id":9096501,"accession":"0001209191-11-043226","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-043226","line_url":"/filing/0001209191-11-043226#line-1","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001341637","owner_name":"Kiley Alison","owner_display_name":"Kiley Alison","owner_url":"/insider/0001341637","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4200.0,"shares_display":"4,200","price_per_share":12.4296,"price_display":"12.43","price_state":"stated","total_value":52204.32,"total_display":"52,204.32","total_whole":"52,204","shares_owned_after":2684751.0,"shares_owned_after_display":"2,684,751","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-08-08","filed_date":"2011-08-09","scope":"insider"},{"id":9251822,"accession":"0001181431-10-054757","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-10-054757","line_url":"/filing/0001181431-10-054757#line-1","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001341637","owner_name":"Kiley Alison","owner_display_name":"Kiley Alison","owner_url":"/insider/0001341637","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":315789.0,"shares_display":"315,789","price_per_share":9.5,"price_display":"9.50","price_state":"stated","total_value":2999995.5,"total_display":"2,999,995.50","total_whole":"2,999,996","shares_owned_after":2680551.0,"shares_owned_after_display":"2,680,551","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-27","filed_date":"2010-11-10","scope":"insider"},{"id":7159810,"accession":"0001181431-10-052254","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-10-052254","line_url":"/filing/0001181431-10-052254#line-4","is_derivative":false,"issuer_cik":"0001338042","issuer_name":"Aegerion Pharmaceuticals, Inc.","issuer_ticker":"AEGR","issuer_name_source":null,"issuer_url":"/issuer/0001338042","owner_cik":"0001341637","owner_name":"Kiley Alison","owner_display_name":"Kiley Alison","owner_url":"/insider/0001341637","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":315789.0,"shares_display":"315,789","price_per_share":9.5,"price_display":"9.50","price_state":"stated","total_value":2999995.5,"total_display":"2,999,995.50","total_whole":"2,999,996","shares_owned_after":2860551.0,"shares_owned_after_display":"2,860,551","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-10-27","filed_date":"2010-10-27","scope":"insider"},{"id":7836335,"accession":"0001209191-07-063353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-07-063353","line_url":"/filing/0001209191-07-063353#line-1","is_derivative":false,"issuer_cik":"0001145197","issuer_name":"INSULET CORP","issuer_ticker":"PODD","issuer_name_source":null,"issuer_url":"/issuer/0001145197","owner_cik":"0001341637","owner_name":"Peyromaure de Bord Alison","owner_display_name":"Peyromaure de Bord Alison","owner_url":"/insider/0001341637","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":511052.0,"shares_display":"511,052","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":1192453.0,"shares_owned_after_display":"1,192,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2007-11-13","filed_date":"2007-11-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001338042","name":"Aegerion Pharmaceuticals, Inc.","url":"/issuer/0001338042","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2010-10-27","last_seen":"2012-10-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001145197","name":"INSULET CORP","url":"/issuer/0001145197","role":"Director","n_filings":1,"first_seen":"2007-11-13","last_seen":"2007-11-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001341637","retrieved_at":"2026-08-27T03:32:17+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}